BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
BIOVIE INC.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 13, 2026
$1.37+0.17 (+14.17%)
Close on Oct 19, 2026
- Market cap
- $10.86M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1M
Shares held, 13F filers
Institutional holders
36
6 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $49.12K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Morgan Stanley Smith Barney LLC | 896,822 | 11.90% | 13G (passive) amendment | Jul 31, 2026 |
| Alta Partners LLC | 687,321 | 8.40% | 13G (passive) | Aug 12, 2026 |
| Jane Street Group, LLC | 441,751 | 5.20% | 13G (passive) | Aug 28, 2026 |
| Do Cuong V | 399,018 | 5.03% | 13D (active) | Jan 5, 2026 |
| Terren S. Peizer | 3,050,394 | 15.80% | 13D (active) amendment | Jun 25, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BIVI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 605,471 | – | $1.17M | +530,250 | 0.00% |
| Diametric Capital, LP | 256,636 | – | $497.87K | −113,364 | 0.05% |
| Renaissance Technologies LLC | 127,918 | – | $248.16K | +60,000 | 0.00% |
| Citadel Advisors LLC | 95,952 | – | $186.15K | +50,660 | 0.00% |
| Vanguard Capital Management LLC | 70,906 | – | $137.56K | −13,161 | 0.00% |
| Geode Capital Management, LLC | 70,752 | – | $137.26K | −13,451 | 0.00% |
| Philadelphia Trust Co | 50,010 | – | $97 | −25,000 | 0.01% |
| Vanguard Fiduciary Trust Co | 37,557 | – | $72.86K | – | 0.00% |
| Jane Street Group, LLC | 35,860 | – | $69.57K | +13,069 | 0.00% |
| Prelude Capital Management, LLC | 32,583 | – | $63.21K | −59,480 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 27,632 | – | $54 | New | 0.00% |
| Northern Trust Corp | 21,820 | – | $42.33K | +7,631 | 0.00% |
| Persistent Asset Partners Ltd | 14,996 | – | $29.09K | New | 0.01% |
| XTX Topco Ltd | 14,228 | – | $27.60K | −6,998 | 0.00% |
| Caprock Group, LLC | 11,300 | – | $21.92K | New | 0.00% |
| Allworth Financial LP | 5,600 | – | $10.86K | – | 0.00% |
| UBS Group AG | 2,175 | – | $4.22K | +2,169 | 0.00% |
| Tower Research Capital LLC (TRC) | 2,064 | – | $4.00K | −5,476 | 0.00% |
| PNC Financial Services Group, Inc. | 1,000 | – | $1.94K | – | 0.00% |
| SBI Securities Co., Ltd. | 867 | – | $1.68K | +636 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 36 | 1M | 6 / 8 | 11 / 3 | 1M | 0M |
| Q1 2026 | 33 | 1M | 7 / 7 | 5 / 7 | 0M | 0M |
| Q4 2025 | 35 | 1M | 7 / 5 | 10 / 4 | 0M | 0M |
| Q3 2025 | 32 | 1M | 31 / 0 | 1 / 0 | 1M | 0M |
| Q2 2025 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BIVI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 70,906 | – | $137.56K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 55,453 | – | $78.74K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 10,898 | – | $15.48K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,401 | – | $3.41K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 230 | – | $327 | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 10 | – | $19 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Cuong V. Do | President & CEO, Director | 26,109 | Aug 28, 2026 |
| Joseph M. Palumbo | Chief Medical Officer | 6,036 | Aug 28, 2026 |
| Joanne Wendy Kim | Chief Financial Officer | 5,441 | Aug 28, 2026 |
| Amy Suzon Chappell | Director | 727 | Aug 28, 2026 |
| Sigmund Rogich | Director | 36,926 | Jan 9, 2026 |
| Kameel D. Farag | Director | – | Jan 9, 2026 |
| James Paul Lang | Director | 68,622 | Jan 9, 2026 |
| Michael Edward Sherman | Director | 20,679 | Jan 9, 2026 |
| Robert J. Hariri | Director | 42,254 | Jan 7, 2025 |
| Richard J. Berman | Director | 40,643 | Jan 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Amy Suzon Chappell Director | Aug 28, 2026 | Buy | +727 | $2.16 | $1.57K | 727 |
| Joseph M. Palumbo Chief Medical Officer | Aug 28, 2026 | Buy | +4,843 | $2.16 | $10.46K | 6,036 |
| Joanne Wendy Kim Chief Financial Officer | Aug 28, 2026 | Buy | +2,500 | $2.18 | $5.45K | 3,441 |
| Cuong V. Do President & CEO, Director | Aug 27, 2026 | Buy | +15,210 | $2.08 | $31.64K | 16,117 |
| Cuong V. Do President & CEO, Director | Aug 7, 2025 | Buy | +5,000 | – | – | 9,992 |
| Sigmund Rogich Director | Nov 20, 2024 | Award | +32,700 | – | – | 36,926 |
| Richard J. Berman Director | Nov 20, 2024 | Award | +34,200 | – | – | 40,643 |
| Joanne Wendy Kim Chief Financial Officer | Jun 24, 2024 | Award | +73,000 | – | – | 112,196 |
| Joanne Wendy Kim Chief Financial Officer | Jun 24, 2024 | Tax withholding | −18,250 | $0.47 | $8.58K | 93,940 |
| Cuong V. Do President & CEO, Director | Jun 24, 2024 | Tax withholding | −42,000 | $0.47 | $19.74K | 551,948 |
| Cuong V. Do President & CEO, Director | Jun 24, 2024 | Award | +168,000 | – | – | 593,948 |
| Joseph M. Palumbo Chief Medical Officer | Jun 24, 2024 | Award | +116,000 | – | – | 148,196 |
| Joseph M. Palumbo Chief Medical Officer | Jun 24, 2024 | Tax withholding | −29,000 | $0.47 | $13.63K | 119,196 |
| Cuong V. Do President & CEO, Director | Mar 4, 2024 | Buy | +10,000 | – | – | 435,854 |
| Joanne Wendy Kim Chief Financial Officer | Feb 15, 2024 | Tax withholding | −2,476 | $1.18 | $2.92K | 39,196 |
| Cuong V. Do President & CEO, Director | Feb 15, 2024 | Tax withholding | −4,953 | $1.18 | $5.84K | 425,948 |
| Joseph M. Palumbo Chief Medical Officer | Feb 15, 2024 | Tax withholding | −2,476 | $1.18 | $2.92K | 32,196 |
| Joanne Wendy Kim Chief Financial Officer | Dec 11, 2023 | Award | +5,000 | – | – | 44,148 |
| Steve Gorlin Director | Dec 1, 2023 | Sale | −75,680 | $1.69 | $127.90K | 46,358 |
| Cuong V. Do President & CEO, Director | Nov 30, 2023 | Buy | +10,000 | $1.78 | $17.80K | 68,759 |
| Steve Gorlin Director | Nov 9, 2023 | Award | +46,358 | – | – | 122,038 |
| Richard J. Berman Director | Nov 9, 2023 | Award | +51,830 | – | – | 69,235 |
| Robert J. Hariri Director | Nov 9, 2023 | Award | +42,254 | – | – | 42,254 |
| Sigmund Rogich Director | Nov 9, 2023 | Award | +42,254 | – | – | 42,254 |
| Steve Gorlin Director | Sep 5, 2023 | Sale | −8,560 | $3.05 | $26.11K | 75,680 |
| Richard J. Berman Director | Aug 22, 2023 | Sale | −10,805 | $3.50 | $37.82K | 16,789 |
| Cuong V. Do CEO & President, Director | Jun 29, 2023 | Award | +149,500 | – | – | 425,854 |
| Cuong V. Do CEO & President, Director | Jun 21, 2023 | Option exercise | +41,506 | – | – | 271,401 |
| Richard J. Berman Director | Jun 7, 2023 | Sale | −5,984 | $5.81 | $34.77K | 23,210 |
| Richard J. Berman Director | May 22, 2023 | Sale | −5,000 | $6.50 | $32.50K | 29,194 |
| Richard J. Berman Director | Mar 28, 2023 | Sale | −2,613 | $8.52 | $22.26K | 34,194 |
| Richard J. Berman Director | Mar 28, 2023 | Sale | −5,000 | $8.52 | $42.60K | 36,807 |
| Richard J. Berman Director | Mar 27, 2023 | Sale | −3,371 | $8.52 | $28.72K | 41,807 |
| Joanne Wendy Kim Chief Financial Officer | Feb 16, 2023 | Tax withholding | −2,476 | $5.51 | $13.64K | 41,672 |
| Cuong V. Do President & CEO, Director | Feb 16, 2023 | Tax withholding | −4,953 | $5.51 | $27.29K | 430,901 |
| Joseph M. Palumbo Chief Medical Officer | Feb 16, 2023 | Tax withholding | −2,476 | $5.51 | $13.64K | 34,672 |
| Clarence N. Ahlem EVP Neuroscience Product Dev. | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 37,148 |
| Penelope Markham EVP Liver Cirrhosis R&D | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 47,841 |
| Joseph M. Palumbo Chief Medical Officer | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 37,148 |
| Cuong V. Do CEO & President, Director | Feb 16, 2023 | Tax withholding | −4,953 | $6.12 | $30.31K | 229,895 |
| Christopher Reading EVP Neuroscience R&D | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 37,148 |
| Joanne Wendy Kim Chief Financial Officer | Feb 16, 2023 | Tax withholding | −2,476 | $6.12 | $15.15K | 39,148 |
| Joseph M. Palumbo Chief Medical Officer | Nov 23, 2022 | Award | +39,624 | – | – | 39,624 |
| Robert J. Hariri Director | Nov 23, 2022 | Award | +34,240 | – | – | 34,240 |
| Penelope Markham EVP Liver Cirrhosis R&D | Nov 23, 2022 | Award | +39,624 | – | – | 50,317 |
| James Paul Lang Director | Nov 23, 2022 | Award | +43,578 | – | – | 68,622 |
| Clarence N. Ahlem EVP Neuroscience Product Dev. | Nov 23, 2022 | Award | +39,624 | – | – | 39,624 |
| Steve Gorlin Director | Nov 23, 2022 | Award | +34,240 | – | – | 84,240 |
| Richard J. Berman Director | Nov 23, 2022 | Award | +43,578 | – | – | 45,178 |
| Christopher Reading EVP Neuroscience R&D | Nov 23, 2022 | Award | +39,624 | – | – | 39,624 |
| Joanne Wendy Kim Chief Financial Officer | Nov 23, 2022 | Award | +39,624 | – | – | 41,624 |
| Cuong V. Do CEO & President, Director | Nov 23, 2022 | Award | +79,248 | – | – | 234,848 |
| Terren S. Peizer Director, 10% owner | Aug 15, 2022 | Award | +3,636,364 | $1.65 | $6.00M | 23,166,210 |
| Jonathan M. Adams EVP Liver Cirrhosis Programs | Feb 2, 2022 | Gift | −1,000 | – | – | 48,630 |
| Cuong V. Do President & CEO, Director | Dec 31, 2021 | Award | +21,710 | – | – | 58,759 |
| Joanne Wendy Kim CFO | Dec 7, 2021 | Buy | +2,000 | $5.40 | $10.80K | 2,000 |
| Jonathan M. Adams EVP Liver Cirrhosis Programs | Jun 16, 2021 | Gift | −10,000 | – | – | 49,630 |
| Terren S. Peizer Director, 10% owner | Jun 10, 2021 | Award | +8,361,308 | – | – | 19,529,846 |
| Steve Gorlin Director | Nov 3, 2020 | Buy | +2,430 | $7.95 | $19.32K | 45,100 |
| Steve Gorlin Director | Oct 30, 2020 | Buy | +2,570 | $7.97 | $20.48K | 42,670 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Gorlin Steve Director | Dec 1, 2023 | 25,680 | $43.40K | Dec 1, 2023 | Performance Stock Units |
| Gorlin Deborah Wife of director Steve Gorlin | Dec 1, 2023 | 50,000 | $84.50K | Dec 1, 2023 | Open Market Purchase |
| Gorlin Steve Director | Sep 5, 2023 | 8,560 | $26.11K | Sep 5, 2023 | Performance Stock Units |